Literature DB >> 17882536

Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant.

Vladimir Nigrovic1, Shashi B Bhatt, Anton Amann.   

Abstract

The study examined in simulations the interaction between a muscle relaxant and an antagonist that binds the free molecules of the relaxant, as experimentally demonstrated for rocuronium and sugammadex. The hypothetical muscle relaxant D and the hypothetical antagonist X were assigned pharmacokinetic properties to define the time course of their concentrations in plasma, and pharmacodynamic properties to define binding of D to either X or the receptors at the motor end plates. D, X, and their complex DX were postulated to diffuse between plasma and the effect compartment. The first and the fourth twitch elicited in sequential trains of four stimuli were evaluated in a model of neuromuscular transmission. The rates of reactions were formulated as differential equations and the equations solved numerically. If the affinity of D for X is comparable to that of D for the postsynaptic receptors, doses of X two to four times larger than the dose of D produce a fast and a complete recovery of the twitches. Smaller doses of X or lower affinities of D for X accomplish a slower and only partial recovery. Additionally, the complete restoration of twitch strength within 2 min after the injection of X requires that X and DX diffuse into the effect compartment. The simulations reveal the physicochemical, pharmacokinetic, and pharmacodynamic properties of an antagonist that restores twitch strength by sequestering the free molecules of the muscle relaxant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882536     DOI: 10.1007/s10928-007-9068-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.410


  24 in total

1.  Modeling of twitch fade based on slow interaction of nondepolarizing muscle relaxants with the presynaptic receptors.

Authors:  Shashi B Bhatt; Anton Amann; Vladimir Nigrovic
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-03       Impact factor: 2.745

2.  Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers.

Authors:  A F Kopman; P S Yee; G G Neuman
Journal:  Anesthesiology       Date:  1997-04       Impact factor: 7.892

3.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

4.  Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block.

Authors:  M Shields; M Giovannelli; R K Mirakhur; I Moppett; J Adams; Y Hermens
Journal:  Br J Anaesth       Date:  2006-01       Impact factor: 9.166

5.  Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.

Authors:  Koen Suy; Karl Morias; Guy Cammu; Pol Hans; Wilbert G F van Duijnhoven; Marten Heeringa; Ignace Demeyer
Journal:  Anesthesiology       Date:  2007-02       Impact factor: 7.892

6.  Anionic cyclophanes as potential reversal agents of muscle relaxants by chemical chelation.

Authors:  Kenneth S Cameron; Lee Fielding; Rona Mason; Alan W Muir; David C Rees; Simon Thorn; Ming Qiang Zhang
Journal:  Bioorg Med Chem Lett       Date:  2002-03-11       Impact factor: 2.823

7.  A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block.

Authors:  Scott B Groudine; Roy Soto; Cynthia Lien; David Drover; Kevin Roberts
Journal:  Anesth Analg       Date:  2007-03       Impact factor: 5.108

8.  Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969.

Authors:  Ola Epemolu; Anton Bom; Frank Hope; Rona Mason
Journal:  Anesthesiology       Date:  2003-09       Impact factor: 7.892

9.  Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey.

Authors:  H D de Boer; J van Egmond; F van de Pol; A Bom; L H D J Booij
Journal:  Br J Anaesth       Date:  2006-02-07       Impact factor: 9.166

10.  Competition between acetylcholine and a nondepolarizing muscle relaxant for binding to the postsynaptic receptors at the motor end plate: simulation of twitch strength and neuromuscular block.

Authors:  Vladimir Nigrovic; Anton Amann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

View more
  2 in total

Review 1.  [Sugammadex. New pharmacological concept for antagonizing rocuronium and vecuronium].

Authors:  H J Sparr; L H Booij; T Fuchs-Buder
Journal:  Anaesthesist       Date:  2009-01       Impact factor: 1.041

2.  Sugammadex.

Authors:  Dennis J Cada; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2016-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.